CRISPR Therapeutics (CRSP) Tops Q3 EPS by 9c
Tweet
Share
E-mail
Get Alerts CRSP Hot Sheet
Join SI Premium – FREE
CRISPR Therapeutics (NASDAQ: CRSP) reported Q3 EPS of ($1.17), $0.09 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $890 thousand versus the consensus estimate of $9.41 million.
For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nelson Peltz Prepares Bid For Wendy’s - FT
- Digital Brands Group forecasts positive cash flow starting in September
- NeOnc Phase 2a brain cancer trial shows 48.9% survival vs. 20% benchmark
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
